198 related articles for article (PubMed ID: 38523704)
1. Engineering LNPs with polysarcosine lipids for mRNA delivery.
Kang DD; Hou X; Wang L; Xue Y; Li H; Zhong Y; Wang S; Deng B; McComb DW; Dong Y
Bioact Mater; 2024 Jul; 37():86-93. PubMed ID: 38523704
[TBL] [Abstract][Full Text] [Related]
2. Polysarcosine-Functionalized mRNA Lipid Nanoparticles Tailored for Immunotherapy.
Wilhelmy C; Keil IS; Uebbing L; Schroer MA; Franke D; Nawroth T; Barz M; Sahin U; Haas H; Diken M; Langguth P
Pharmaceutics; 2023 Aug; 15(8):. PubMed ID: 37631282
[TBL] [Abstract][Full Text] [Related]
3. Polysarcosine-based lipid formulations for intracranial delivery of mRNA.
Bi D; Unthan DM; Hu L; Bussmann J; Remaut K; Barz M; Zhang H
J Control Release; 2023 Apr; 356():1-13. PubMed ID: 36803765
[TBL] [Abstract][Full Text] [Related]
4. Tailored Monoacyl Poly(2-oxazoline)- and Poly(2-oxazine)-Lipids as PEG-Lipid Alternatives for Stabilization and Delivery of mRNA-Lipid Nanoparticles.
He X; Payne TJ; Takanashi A; Fang Y; Kerai SD; Morrow JP; Al-Wassiti H; Pouton CW; Kempe K
Biomacromolecules; 2024 Jun; ():. PubMed ID: 38918933
[TBL] [Abstract][Full Text] [Related]
5. Investigations into mRNA Lipid Nanoparticles Shelf-Life Stability under Nonfrozen Conditions.
Reinhart AG; Osterwald A; Ringler P; Leiser Y; Lauer ME; Martin RE; Ullmer C; Schumacher F; Korn C; Keller M
Mol Pharm; 2023 Dec; 20(12):6492-6503. PubMed ID: 37975733
[TBL] [Abstract][Full Text] [Related]
6. Development of Lipid Nanoparticle Formulation for the Repeated Administration of mRNA Therapeutics.
Lee Y; Jeong M; Lee G; Park J; Jung H; Im S; Lee H
Biomater Res; 2024; 28():0017. PubMed ID: 38779139
[TBL] [Abstract][Full Text] [Related]
7. Predictive high-throughput screening of PEGylated lipids in oligonucleotide-loaded lipid nanoparticles for neuronal gene silencing.
Sarode A; Fan Y; Byrnes AE; Hammel M; Hura GL; Fu Y; Kou P; Hu C; Hinz FI; Roberts J; Koenig SG; Nagapudi K; Hoogenraad CC; Chen T; Leung D; Yen CW
Nanoscale Adv; 2022 May; 4(9):2107-2123. PubMed ID: 36133441
[TBL] [Abstract][Full Text] [Related]
8. On the Influence of Fabrication Methods and Materials for mRNA-LNP Production: From Size and Morphology to Internal Structure and mRNA Delivery Performance In Vitro and In Vivo.
Bi D; Wilhelmy C; Unthan D; Keil IS; Zhao B; Kolb B; Koning RI; Graewert MA; Wouters B; Zwier R; Bussmann J; Hankemeier T; Diken M; Haas H; Langguth P; Barz M; Zhang H
Adv Healthc Mater; 2024 Jun; ():e2401252. PubMed ID: 38889433
[TBL] [Abstract][Full Text] [Related]
9. CHARMM-GUI Membrane Builder for Lipid Nanoparticles with Ionizable Cationic Lipids and PEGylated Lipids.
Park S; Choi YK; Kim S; Lee J; Im W
J Chem Inf Model; 2021 Oct; 61(10):5192-5202. PubMed ID: 34546048
[TBL] [Abstract][Full Text] [Related]
10. Lipid nanoparticle formulations for optimal RNA-based topical delivery to murine airways.
Tam A; Kulkarni J; An K; Li L; Dorscheid DR; Singhera GK; Bernatchez P; Reid G; Chan K; Witzigmann D; Cullis PR; Sin DD; Lim CJ
Eur J Pharm Sci; 2022 Sep; 176():106234. PubMed ID: 35688311
[TBL] [Abstract][Full Text] [Related]
11. Analysis of PEG-lipid anchor length on lipid nanoparticle pharmacokinetics and activity in a mouse model of traumatic brain injury.
Waggoner LE; Miyasaki KF; Kwon EJ
Biomater Sci; 2023 Jun; 11(12):4238-4253. PubMed ID: 36987922
[TBL] [Abstract][Full Text] [Related]
12. Bile acid-containing lipid nanoparticles enhance extrahepatic mRNA delivery.
Patel SK; Billingsley MM; Mukalel AJ; Thatte AS; Hamilton AG; Gong N; El-Mayta R; Safford HC; Merolle M; Mitchell MJ
Theranostics; 2024; 14(1):1-16. PubMed ID: 38164140
[TBL] [Abstract][Full Text] [Related]
13. Anti-PEG antibodies before and after a first dose of Comirnaty® (mRNA-LNP-based SARS-CoV-2 vaccine).
Bavli Y; Chen BM; Gross G; Hershko A; Turjeman K; Roffler S; Barenholz Y
J Control Release; 2023 Feb; 354():316-322. PubMed ID: 36549393
[TBL] [Abstract][Full Text] [Related]
14. Chemistry of Lipid Nanoparticles for RNA Delivery.
Eygeris Y; Gupta M; Kim J; Sahay G
Acc Chem Res; 2022 Jan; 55(1):2-12. PubMed ID: 34850635
[TBL] [Abstract][Full Text] [Related]
15. Anti-PEG Antibodies Boosted in Humans by SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine.
Ju Y; Lee WS; Pilkington EH; Kelly HG; Li S; Selva KJ; Wragg KM; Subbarao K; Nguyen THO; Rowntree LC; Allen LF; Bond K; Williamson DA; Truong NP; Plebanski M; Kedzierska K; Mahanty S; Chung AW; Caruso F; Wheatley AK; Juno JA; Kent SJ
ACS Nano; 2022 Aug; 16(8):11769-11780. PubMed ID: 35758934
[TBL] [Abstract][Full Text] [Related]
16. Effect of PEG Anchor and Serum on Lipid Nanoparticles: Development of a Nanoparticles Tracking Method.
Berger M; Degey M; Leblond Chain J; Maquoi E; Evrard B; Lechanteur A; Piel G
Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839919
[TBL] [Abstract][Full Text] [Related]
17. Substituting Poly(ethylene glycol) Lipids with Poly(2-ethyl-2-oxazoline) Lipids Improves Lipid Nanoparticle Repeat Dosing.
Sanchez AJDS; Loughrey D; Echeverri ES; Huayamares SG; Radmand A; Paunovska K; Hatit M; Tiegreen KE; Santangelo PJ; Dahlman JE
Adv Healthc Mater; 2024 Feb; ():e2304033. PubMed ID: 38318754
[TBL] [Abstract][Full Text] [Related]
18. From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases.
Pilkington EH; Suys EJA; Trevaskis NL; Wheatley AK; Zukancic D; Algarni A; Al-Wassiti H; Davis TP; Pouton CW; Kent SJ; Truong NP
Acta Biomater; 2021 Sep; 131():16-40. PubMed ID: 34153512
[TBL] [Abstract][Full Text] [Related]
19. Development of a high-throughput platform for screening lipid nanoparticles for mRNA delivery.
Cui L; Pereira S; Sonzini S; van Pelt S; Romanelli SM; Liang L; Ulkoski D; Krishnamurthy VR; Brannigan E; Brankin C; Desai AS
Nanoscale; 2022 Jan; 14(4):1480-1491. PubMed ID: 35024714
[TBL] [Abstract][Full Text] [Related]
20. Investigating Generation of Antibodies against the Lipid Nanoparticle Vector Following COVID-19 Vaccination with an mRNA Vaccine.
Münter R; Sørensen E; Hasselbalch RB; Christensen E; Nielsen SD; Garred P; Ostrowski SR; Bundgaard H; Iversen KK; Andresen TL; Larsen JB
Mol Pharm; 2023 Jul; 20(7):3356-3366. PubMed ID: 36952227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
